[Biomarkers in endocrinology].
d'Herbomez M, Bauters C, Cortet-Rudelli C, Dewailly D, Docao C, Wémeau JL.
Presse Med. 2014 Jan;43(1):40-56. doi: 10.1016/j.lpm.2013.11.003. Epub 2013 Dec 15.
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24. doi: 10.1967/s002449910163. Epub 2015 Feb 13.
Thyroid nodules: alpha guide to assessment, treatment and follow-up.
Paschou SA, Vryonidou A, Goulis DG.
Maturitas. 2017 Feb;96:1-9. doi: 10.1016/j.maturitas.2016.11.002. Epub 2016 Nov 9.
Medullary thyroid carcinoma and calcitonin.
Emmertsen K.
Dan Med Bull. 1985 Mar;32(1):1-28.
Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.
Wüster C, Raue F, Meyer C, Bergmann M, Ziegler R.
J Endocrinol. 1992 Jul;134(1):141-7. doi: 10.1677/joe.0.1340141.
Calcitonin. A review of experimental and clinical investigations.
Foster GV.
Postgrad Med J. 1968 May;44(511):411-22. doi: 10.1136/pgmj.44.511.411.
Calcitonin: physiology or fantasy?
Davey RA, Findlay DM.
J Bone Miner Res. 2013 May;28(5):973-9. doi: 10.1002/jbmr.1869.
[How to interprete hypercalcitoninemia?].
Levy-Bohbot N, Patey M, Larbre H, Hecart AC, Caron J, Delemer B.
Rev Med Interne. 2006 Aug;27(8):610-5. doi: 10.1016/j.revmed.2006.02.010. Epub 2006 Apr 19.
Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
Ongphiphadhanakul B, Alex S, Braverman LE, Baran DT.
J Bone Miner Res. 1992 Oct;7(10):1227-31. doi: 10.1002/jbmr.5650071015.
Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F, Frank-Raue K.
Recent Results Cancer Res. 2015;204:207-25. doi: 10.1007/978-3-319-22542-5_10.
